Overview : BSI-04702 is an anti-TROP2 humanized monoclonal antibody created by Biosion’s proprietary SynTracerTM internalization platform. TROP2 is highly expressed in various cancer cells, such as pancreatic, gastric, lung, colorectal cancer cells, and its overexpression is associated with poor survival in patients with solid tumors. In Dec 2021, Biosion licensed ex-Greater China rights of BSI-04702 to OBI Pharma.

Development status : OBI Pharma plans to file an IND in 2H 2023.